Celecoxib-induced deep-vein thrombosis.
Chan
Agnes L F
AL
D000925:Anticoagulants / Q000627:therapeutic use; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000627:therapeutic use; D006073:Gout / Q000188:drug therapy; D006801:Humans; D019934:International Normalized Ratio / Q000379:methods; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time / Q000379:methods; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D016861:Cyclooxygenase Inhibitors; D017984:Enoxaparin; D011720:Pyrazoles; D013449:Sulfonamides; D014859:Warfarin; D000068579:Celecoxib